Biotech Co.*
(Country;
Symbol)#

Pharma Co.
(Country)

Type/Product Area

Terms/Details (Date)


Ablynx NV*
(Belgium)

Procter & Gamble Co.

They extended existing deal to include metabolic disease targets provided by P&G

Ablynx is entitled to R&D funding, milestone payments and royalties on resulting products; it is using its Nanobody platform in the effort (4/10)

Advanced
Biotherapy Inc.
(OTC BB:ADVB)

Battelle

Deal to develop monoclonal antibodies to treat humans and animals exposed to anthrax and plague, as well as for autoimmune diseases

They entered a memorandum of understanding as a basis for jointly participating in the Initiatives for Proliferation Prevention projects of the U.S. Department of Energy (3/22)

Affymetrix
Inc.
(AFFX)

Abbott Molecular

Abbott got nonexclusive rights to a number of Affymetrix patents

The patents will allow Abbott to make and sell comparative genomic hybridization microarrays, related readers and software in the research and diagnostics field (4/5)

Amgen Inc.
(AMGN)

Alcon Inc.

Deal to research, develop and market therapeutics for treating eye diseases; the deal covers multiple targets and indications

Amgen will provide molecules to the effort, while Alcon would get exclusive rights to resulting candidates in ophthalmology; Amgen either could share profits on resulting products or be entitled to milestone and royalty payments (4/24)

Argos
Therapeutics
Inc.*

Beckman Coulter Inc.

Argos got exclusive therapeutic use rights for the soluble protein CD83

Terms include use as a therapy for autoimmune disorders and transplant rejection; Beckman retained rights to CD83 in diagnostics; terms were not disclosed (4/26)

Argos
Therapeutics
Inc.*

Novo Nordisk A/S (Denmark)

Novo got rights to antibody technology designed to treat systemic immune disorders, including lupus

Argos will get up to $69M in up-front and milestone payments, in addition to royalties on any resulting sales (3/14)

Arius
Research Inc.
(Canada; CDNX:
ARI)

Takeda Pharmaceutical Co. Ltd. (Japan)

Collaboration to use Arius' FunctionFIRST platform to discover treatments for human diseases

Arius gets a $1M access fee and a $1M equity investment up front and research funding for three years; it also is entitled to milestone and royalty payments based on any licensed products (4/3)

Artemis
Pharmaceuticals
GmbH
(Germany;
subsidiary of
Exelixis Inc.;
EXEL)

Bristol-Myers Squibb Co.

Deal under which Artemis will generate genetically engineered murine models carrying selected genetic mutations

BMS will use the models for validating drug screening targets; Artemis will do certain work with partner Taconic Farms Inc. (2/28)

AVI BioPharma
Inc.
(AVII)

Cook Group Inc.

Cook licensed AVI's Neugene antisense technology for down- regulating c-myc gene expression in the field of cardiovascular disease

Cook will take over development of AVI's device- related programs for cardiovascular restenosis; Cook will buy $5M of AVI stock; AVI also would get double-digit royalties and a commercialization milestone payment (3/13)

BG Medicine
Inc.*

Mitsubishi Pharma Corp. (Japan)

Deal for a preclinical study into the biochemical origins of muscle toxicity and associated biomarkers

BG Medicine will apply its toxicology platform in the study of two lipid-lowering compounds; they will jointly own certain rights to resulting data (3/28)

Biogen Idec
Inc.
(BIIB)

Astellas Pharma US Inc.

Astellas is buying worldwide rights to Amevive, a drug approved for treating plaque psoriasis

Biogen gets $60M and undisclosed royalties under the deal, which covers all indications; it also will continue to manufacture the product (4/3)

Biosite Inc.
(BSTE)

Eli Lilly and Co.

Biosite will develop a diagnostic for measuring Protein C levels for trials of Lilly's sepsis drug, Xigris

Lilly will use the test in enrollment for an upcoming Phase IIb trial; Biosite gets rights to resulting technology in sepsis diagnosis; terms were not disclosed (3/20)

BioSystems
International*
(France)

AstraZeneca plc (UK)

BSI will perform biomarker discovery services for AstraZeneca in osteoarthritis

BSI retains rights to diagnostic applications; AstraZeneca gets nonexclusive rights to use results for R&D activities and exclusive rights to any new targets (2/23)

Cell Signaling
Technology
Inc.*

AstraZeneca plc (UK)

CST will identify phosphorylation profiles and biomarkers of kinase-targeted lead compounds for AstraZeneca

It is the third agreement in the area between the companies; terms of the deal were not disclosed (4/12)

ChemDiv Inc.*

Berlex Inc. (unit of Schering AG; Germany)

Collaboration to discover lead compounds against several selected GPCR targets

ChemDiv will apply its chemistry capabilities in the deal, terms of which were not disclosed (3/10)

Codexis Inc.*

Schering-Plough Corp.

Deal to improve biocatalyst productivity at Schering- Plough using Codexis' MolecularBreeding platform

Codexis will receive research funding and could get milestone payments in the deal (3/21)

Crucell NV
(the Netherlands;
CRXL) and DSM
Biologics (the
Netherlands)

UCB SA (Belgium)

UCB got rights to evaluate the PER.C6 cell line for research and manufacturing of monoclonal antibodies

Terms of the deal were not disclosed (3/14)

Crucell NV
(the Netherlands;
CRXL) and DSM Biologics (the
Netherlands)

UMN Pharma (Japan)

UMN Pharma got rights to use the PER.C6 cell line in development of a fusion protein for treating various diseases

Crucell and DSM get a signing fee and annual maintenance fees, as well as fees for services; UMN's focus is on muscular dystrophy and metabolic diseases (3/9)

Cytori
Therapeutics
Inc.
(CYTX)

Olympus Corp. (Japan)

Olympus got an option to use adipose stem and regenerative cells for a specific area outside of cardiovascular disease

Olympus is paying $1.5M for the exclusive right to negotiate a deal in that area; further terms were not disclosed (2/23)

DigitalBiotech
Co. Ltd.*
(South Korea)

Grunenthal GmbH (Germany)

Collaboration to discover and develop vanilloid receptor antagonists for treating pain

Grunenthal will fund research and would market resulting products; terms were not disclosed (3/21)

Elixir
Pharmaceuticals
Inc.*

Kissei Pharmaceutical Co. Ltd. (Japan)

Elixir got North American rights to the insulin secretagogue Glufast, which is on the market in Japan

The product targets Type II diabetes; Kissei is entitled to milestone and royalty payments in the deal (3/27)

Emisphere
Technologies
Inc.
(EMIS)

Novartis AG (Switzerland)

Novartis executed its option to develop an oral parathyroid hormone using Emisphere's eligen delivery technology

Emisphere is eligible for milestone payments of up to $30M, as well as royalties on resulting sales (3/8)

Entelos Inc.*

Johnson & Johnson Pharmaceutical Research & Development LLC

They expanded collaboration to include multiple therapeutic areas over a five-year term

Entelos is applying its PhysioLab platform, which simulates human biology, to programs at J&J; terms of the deal were not disclosed (3/16)

Exelixis Inc.(EXEL)

Daiichi Sankyo Co. Ltd. (Japan)

Collaboration to discover and market therapies targeted against the mineralocorticoid receptor, which is implicatedin certain cardiovascular and metabolic diseases

Exelixis gets $20M in up-front and research funding, as well as potential milestone payments and double-digit sales royalties; Exelixis said it would get $70M in guaran- teed near term payments and could get $1B in milestone payments (3/20)

FivePrime
Therapeutics
Inc.*
(Germany)

Boehringer Ingelheim GmbH

Two-year, multiproduct deal to develop therapeutics for rheumatoid arthritis and other diseases

FivePrime gets an up-front fee and research support in the potential $75M deal and could get milestone and royalty payments; BI gets exclusive rights to resulting products (4/25)

Galapagos NV (Belgium; Euronext:GLPG)

F. Hoffmann- La Roche Ltd. (Switzerland)

Deal under which Galapagos will supply Roche with exclusive chemical compound libraries

The three-year deal involves Galapagos' BioFocus division; terms were not disclosed (3/28)

GeneGo Inc.*

Berlex Inc. (unit of Schering AG; Germany)

Berlex got rights to use the MetaCore platform for analysis of gene expression and other high- throughput data

Berlex got rights in multiple therapeutic areas, including diagnostics; terms of the deal were not disclosed (3/13)

Gene Logic
Inc.
(GLGC)

NV Organon (the Netherlands)

Deal to seek alternative development paths for drug candidates previously discontinued by Organon

Gene Logic will use its repositioning technology to seek new uses for the compounds, for which Gene Logic could earn milestone payments; resulting candidates would be equally owned (4/21)

Genentech
Inc.
(NYSE:DNA)

BioWa Inc. (unit of Kyowa Hakko Kogyo Co. Ltd.; Japan)

Genentech got exclusive rights to use Potelligent technology for multiple antibodies

The technology is designed to improve the activity of antibodies; BioWa gets technology access fees and could get milestone and royalty payments (3/24)

Idenix
Pharmaceuticals
Inc.
(IDIX)

Novartis AG (Switzerland)

Novartis exercised its option to license valopicitabine (NM283), an oral agent in Phase IIb trials for treating hepatitis C

Idenix gets $25M up front and $45M more upon the start of Phase III trials in the U.S.; Idenix could get up to $455M in milestone payments; Idenix would co-promote the drug in the U.S. and the five major European markets (3/29)

IDM Pharma
Inc.
(IDMI)

Medison Pharma (Israel)

Medison got rights in Israel to Junovan, an immune system stimulator for treating cancer

IDM gets an up-front license fee and would get a milestone payment upon approval in Israel, as well as royalties on sales (3/14)

ImQuest
Pharmaceuticals
Inc.*

Samjin Pharmaceutical Co. Ltd. (South Korea)

ImQuest got rights outside Korea to Samjin's piperazine series of anticancer compounds

There are 105 compounds included in the deal, some at the late preclinical stage; terms were not disclosed (4/26)

ImQuest
Pharmaceuticals
Inc.*

Samjin Pharmaceutical Co. Ltd. (South Korea)

ImQuest got rights to the entire pyrimidinedione series of anti-HIV compounds discovered by Samjin

The deal follows one from January under which ImQuest agreed to provide development support to Samjin; terms were not disclosed (2/28)

Infinity
Pharmaceuticals
Inc.*

Novartis AG (Switzerland)

Deal to discover and commercialize drugs targeting Bcl-2 protein family members for treating a range of cancers

Infinity gets $30M up front, along with an equity investment and committed research funding over two years; with milestones, total payments could exceed $400M; Infinity also would get royalties on sales and another equity investment if it goes public and has a U.S. co-promotion option (3/6)

Innate
Pharma SA*
(France)

Novo Nordisk A/S (Denmark)

Collaboration to develop drugs targeting natural killer cells, for a variety of indications

Innate is getting an €8M equity investment and is entitled to €25M in up-front R&D and preclinical milestone payments over a three-year term; it also could get €25M in milestone payments per compound and royalties on resulting sales (4/5)

Medarex Inc.
(MEDX)

Ono Pharmaceutical Co. Ltd. (Japan)

Collaboration to develop a fully human antibody against stromal cell-derived factor 1 for multiple indications

They will share costs through Phase II trials, after which each would be responsible in its own territories: Medarex in North America and Ono elsewhere (3/28)

Memory
Pharmaceuticals
Corp.
(MEMY)

F. Hoffmann- La Roche Ltd. (Switzerland)

Expanded deal gives Roche worldwide rights to nicotinic alpha-7 receptor compounds, excluding MEM 3454, which remain subject to the original option agreement

Memory could receive $2.3M in research funding during 2007 and is entitled to additional milestones payments; Memory will conduct Phase I trials for resulting compounds, while Roche would be responsible for later-stage development and commercialization (2/28)

MorphoSys
AG
(Germany;
FSE:MOR)

Daiichi Sankyo Co. Ltd. (Japan)

Collaboration to develop antibodies based on MorphoSys' HuCAL Gold technology

Daiichi will start one antibody program and has an option on further programs; MorphoSys gets an up-front payment and research funding and could get licensing, milestone and royalty payments (3/16)

MorphoSys
AG
(Germany;
FSE:MOR)

F. Hoffmann- La Roche Ltd. (Switzerland)

MorphoSys will generate antibodies against oncology targets provided by Roche

The deal covers two antibody programs; MorphoSys gets an up-front payment and could get research funding and milestone payments totaling more than €10M per program, plus royalties on sales (3/1)

Myogen Inc.z
(MYOG)

GlaxoSmithKline plc(UK)

Two-part collaboration in pulmonary arterial hypertension: GSK got rights outside the U.S. to ambrisentan, while Myogen gained U.S. marketing responsibility for GSK's Flolan

Myogen gets $20M up front and up to $80M more in milestone payments; it would get royalties averaging in the mid-20% range; under the three-year Flolan deal, which has a renewal option, Myogen will build a sales organization (3/6)

Myriad
Genetics Inc.
(MYGN)

Abbott Laboratories

Five-year agreement to identify therapeutic targets for a variety of diseases

Myriad will receive about 40% of the targets with associated lead compounds identified under the deal, and Abbott about 60%; terms were not disclosed (4/11)

Nabi Bio-
pharmaceuticals
(NABI)

Fresenius Biotech GmbH (Germany)

Nabi gets exclusive rights in the U.S. and Canada to ATG- Fresenius S, a polyclonal antibody for use in transplant rejection

Fresenius will get up to $1M in development milestones and would get $4M upon FDA approval; it also would get royalty payments (4/3)

Nanogen Inc.
(NGEN)

Fisher Scientific International Inc.

Deal to expand the use of markers and diagnostic assays from Athena Diagnostics Inc.

Fisher had just acquired Athena when the deal was made with Nanogen; Fisher made a $15M equity investment in Nanogen; further terms were not disclosed (3/16)

Nastech
Pharmaceutical
Co. Inc.
(NSTK)

Novo Nordisk A/S (Denmark)

They entered a multi-compound, feasibility study agreement covering certain Novo compounds

The compounds, indications and terms of the deal were not disclosed (3/15)

Neuromed
Pharmaceuticals
Ltd.*

Merck & Co. Inc.

Merck got worldwide rights to compounds for treating pain and other neurological disorders, including the Phase II product NMED-160

Neuromed gets a $25M payment up front and at least two years of research funding; milestone payments would total $202M if NMED-160 was launched in one indication and would total $450M if additional drugs and indications are developed; Neuromed would get royalties on any sales and has certain U.S. co-promotion options (3/20)

NicOx SA
(France;
Eurolist:NICOX)

Merck & Co. Inc.

Collaboration to develop antihypertensive drugs using NicOx's nitric oxide-donating technology

NicOx gets $11.2M up front and could get milestone payments of $340.2M, as well as royalties on resulting sales; it also retained certain co-promotion options in the U.S. and Europe (3/21)

NicOx SA
(France;
Eurolist:NICOX)

Pfizer Inc.

Pfizer got exclusive rights across the entire field of ophthalmology to use NicOx's nitric oxide-donating technology

NicOx gets €8M up front and a €15M equity investment at a 4.9% premium; NicOx also could earn milestone payments of €102M for the first ophthalmology program and up to €194.3M more if an indication outside ophthalmology is developed; NicOx also would get royalties on sales (3/2)

Noxxon
Pharma AG*
(Germany)

Pfizer Inc.

Collaboration to develop products based on Noxxon's Spiegelmer technology; Pfizer also got rights to the preclinical product NOX- 11, a ghrelin-binding agent for obesity

Noxxon gets up-front payments for each deal, and could get milestone and royalty payments; Pfizer also will make an equity investment in Noxxon; Pfizer will have the option to collaborate on up to three targets per year in the first collaboration (3/23)

OriGene
Technologies
Inc.*

Bayer HealthCare AG (Germany)

Bayer acquired access to OriGene's collection of full-length cDNA clones

Bayer got access to OriGene's TrueClone Collection; terms of the deal were not dis- closed (3/13)

OrthoLogic
Corp.
(OLGC)

Quintiles Transnational Corp.

Deal for the development and commercialization of Chrysalin (TP508), a synthetic peptide from OrthoLogic

Quintiles will exclusively provide clinical research services, and will have the right of first negotiation to promote Chrysalin upon FDA approval; OrthoLogic also will receive an equity investment of up to $5M (2/28)

Paratek
Pharmaceuticals
Inc.*

Merck & Co. Inc.

Worldwide deal to develop Paratek's PTK 0796, a broad- spectrum antibiotic in Phase I trials

Paratek gets an up-front payment and could receive up to $127M in milestone payments through approval; it also would get royalties on sales and has a option to co-promote the I.V. formulation in the U.S. (3/9)

Pharmacopeia
Drug Discovery
Inc.
(PCOP)

Bristol-Myers Squibb Co.

Pharmacopeia got rights to BMS compounds that possess dual angiotensin and endothelin receptor antagonist activity

Pharmacopeia will provide BMS with a set of compound libraries; BMS is entitled to milestone and royalty payments under the exclusive, worldwide licensing deal (4/3)

Pharmacopeia
Drug Discovery
Inc.
(PCOP)

GlaxoSmithKline plc (UK)

Deal under which Pharmacopeia will discover molecules for development by GSK in multiple therapeutic areas

GSK gets exclusive options to conduct Phase III trials and to commercialize resulting products; Pharmacopeia gets $15M in the deal and could get up to $83M in milestones, plus double-digit royalties, on each resulting product (3/30)

Pieris
Proteolab AG*
(Germany)

GE Healthcare

Collaboration to discover targeted in vivo diagnostic and medical imaging compounds

Pieris will use its Anticalin technology to select protein ligands to two targets selected by GE, which then could develop resulting imaging agents; Pieris retains therapeutic rights; terms were not disclosed (4/24)

Praecis
Pharmaceuticals
Inc.
(PRCS)

GlaxoSmithKline plc (UK)

Praecis will apply its Direct- Select technology to identify small- olecule drug candidates against four GSK targets

GSK has an option to enter a deal on resulting lead compounds; Praecis is getting a $0.5M equity investment and could get $1M in milestone payments during the pilot phase of the deal (4/10)

ProMetic Life Sciences Inc.
(Canada; TSE:
PLISV)

Sartorius AG (Germany)

Collaboration to use bioseparation systems to recover proteins from human blood plasma

They also will combine membrane and ligand technologies for expanded product offerings; terms were not disclosed (4/3)

PsychoGenics
Inc.*

Sosei Co. Ltd. (Japan)

Collaboration to discover and develop therapies for central nervous system diseases

Each will bring technologies to the effort, which focuses on Sosei compounds was previously discontinued; terms were not disclosed (4/10)

PTC
Therapeutics
Inc.*

Schering-Plough Corp.

Collaboration to develop PTC's preclinical compounds for the oral treatment of hepatitis C and other viral diseases

PTC gets $12M up front and research funding; with milestones, payments to PTC could exceed $200M; it also would get royalties on worldwide sales (3/20)

Sepracor Inc.
(SEPR)

UCB SA (Belgium)

UCB got exclusive rights in the U.S. to the antihistamine levocetirizine

Separacor would get royalties on sales; UCB already sells the product in Europe, where Sepracor earns royalties (2/23)

SGX
Pharmaceuticals
Inc.
(SGXP)

Novartis AG (Switzerland)

Deal to develop and market BCR-ABL inhibitors for treating drug- resistant chronic myelogenous leukemia

SGX gets $25M up front in cash and the purchase of stock and two years of R&D funding; payments, including milestones, could total $515M; SGX also would get royalties on resulting sales (3/27)

Signet
Laboratories
Inc.*

Bayer Diagnostics Inc.

Signet will conduct research on urinary trypsin inhibitor immunoassays discovered by Bayer

Signet will evaluate the utility of the trypsin inhibitors as biomarkers for acute renal failure in pilot trials that are under way; terms were not disclosed (3/1)

Sirna
Therapeutics
Inc.
(RNAI)

GlaxoSmithKline plc (UK)

Collaboration to discover and market RNA interference-based therapeutics for respiratory diseases

Sirna gets $12M up front in a cash payment and equity investment and could get more than $700M in milestone payments, as well as royalties on resulting sales; it also could receive manufacturing revenues (4/3)

Spectrum
Pharmaceuticals
Inc.
(SPPI)

Par Pharmaceutical Co. Inc.

Collaboration under which Par got rights to develop and market generic drugs

Spectrum will develop products, and Par would market them in the U.S.; Spectrum would get milestone payments for each successfully developed product, and share in any resulting profits (2/23)

Stratagene
Corp.
(STGN)

Bayer HealthCare Corp.

Bayer will purchase Mx3005P instrument systems for use in a new platform it is developing

Stratagene will customize the instrument for use in the molecular diagnostics platform (3/14)

Third Wave
Technologies
Inc.
(TWTI)

Mitsubishi Corp. (Japan)

They formed a joint venture focused on clinical molecular diagnostics and pharmaco- genetics in Asia

The focus is on accelerating and expanding development of products for the the Japanese molecular diagnostics market; Mitsubishi will own about 14% of Third Wave Japan when the deal closes (4/5)

Tripos Inc.
(TRPS)

Abbott Laboratories

Chemistry collaboration to expand Abbott's compound file collection

They intend to design, synthesize and purify novel, drug-like compounds; terms were not disclosed (3/20)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.